Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Shorts Strengthened By 9.18%

June 29, 2018 - By Joseph Taylor

It was reported an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s short interest with 9.18%. FINRA announced short interest of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s former position will take 42 days to recover. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

The stock increased 0.54% or $0.07 during the last trading session, hitting $13.Currently Zealand Pharma A/S is after 0.00% change in last June 29, 2017. ZEAL has 3,000 shares volume. ZEAL underperformed by 12.57% the S&P500.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is worth $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Currently it has negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were recently released by: Streetinsider.com on June 08, 2018 with title “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives”. The other Seekingalpha.com‘s article was titled “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved” and released on June 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: